Biora Therapeutics Stock Fair Value Calculation – Biora Therapeutics’ Debt Takes a 46.87% Hit in the Last Three Months
March 2, 2023
Trending News 🌧️
Biora Therapeutics Stock Fair Value Calculation – Over the last three months, Biora Therapeutics ($NASDAQ:BIOR) Inc. has seen its share price take a notable hit. During this period, the company’s debt has had a major impact on the share price. This decline came as investors showed increasing uncertainty towards their investments in the company. In particular, their worries concerning the company’s high level of debt were taken into account when making their decisions.
The high amount of debt that Biora Therapeutics holds is largely attributed to the company’s rapid expansion and the acquisitions they have made over the past few years. This has put a significant strain on the company’s finances and led to concerns from investors. With a much lower share price and a more manageable level of debt, the company’s growth prospects are looking much more favorable than before.
Market Price
On Wednesday, the stock opened at $3.0 and closed at $3.0, which was a decrease of 3.6% from its previous closing price of $3.1. This downturn in the debt position of BIORA THERAPEUTICS is a concern among investors, who are watching and waiting to see how the company will respond to this situation. The company has yet to comment on the issue, but investors are sure to be looking for a positive response and will be looking at their financial statements closely. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Biora Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 0.73 | -117.31 | -11773.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Biora Therapeutics. More…
| Operations | Investing | Financing |
| -93.44 | -0.51 | 76.32 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Biora Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 62.61 | 160.06 | -12.88 |
Key Ratios Snapshot
Some of the financial key ratios for Biora Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -78.6% | – | -8304.0% |
| FCF Margin | ROE | ROA |
| -12970.4% | 38.9% | -60.2% |
Analysis – Biora Therapeutics Stock Fair Value Calculation
A t G o o d W h a l e , w e a n a l y z e d t h e f u n d a m e n t a l s o f B I O R A T H E R A P E U T I C S t o d e t e r m i n e i t s f a i r v a l u e . O u r p r o p r i e t a r y V a l u a t i o n L i n e d e t e r m i n e d t h a t t h e f a i r v a l u e o f i t s s t o c k i s a r o u n d $ 7 . 4 . C u r r e n t l y , t h e m a r k e t p r i c e o f B I O R A T H E R A P E U T I C S i s t r a d i n g a t o n l y $ 3 . 2 % d i f f e r e n c e f r o m t h e f a i r v a l u e w e c a l c u l a t e d . A s s u c h , i t i s o u r o p i n i o n t h a t B I O R A T H E R A P E U T I C S i s c u r r e n t l y u n d e r v a l u e d b y t h e m a r k e t. More…
Peers
The competition in the field of cancer therapeutics is heating up, with Biora Therapeutics Inc taking on NuCana PLC, GT Biopharma Inc, and CytomX Therapeutics Inc. While each company has its own unique approach to cancer treatment, they are all striving to be the best in the field. May the best company win!
– NuCana PLC ($NASDAQ:NCNA)
NuCana PLC is a pharmaceutical company that focuses on the development and commercialization of cancer treatments. The company has a market capitalization of $52.2 million and a return on equity of -44.76%. NuCana PLC’s products are designed to improve the treatment of cancer by targeting the disease at the cellular level. The company’s products are in various stages of development, including clinical trials.
– GT Biopharma Inc ($NASDAQ:GTBP)
ACGT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapies for the treatment of cancer. The company’s lead product candidates are ACGT087, a monoclonal antibody targeting CD73, and ACGT141, a monoclonal antibody targeting CTLA-4. ACGT Biopharma Inc is headquartered in San Diego, California.
– CytomX Therapeutics Inc ($NASDAQ:CTMX)
CytomX Therapeutics Inc is a clinical-stage biopharmaceutical company developing a novel class of investigational antibody therapeutics based on its Probody platform. The Probody platform is designed to improve the therapeutic index of antibodies by targeting them to cancer cells while limiting exposure to healthy tissues. CytomX’s lead product candidate, CX-072, is an anti-CD166 Probody therapeutic antibody in Phase 1 clinical testing for the treatment of solid tumors.
Summary
Investors in Biora Therapeutics should take heed of the company’s recent stock performance and debt situation. This indicates that there is risk associated with investing in Biora Therapeutics and should give investors pause when considering investing or further investing in the company. It is recommended that investors thoroughly research Biora Therapeutics before making a decision to invest capital.
